The Center for Personalized Diagnostics (CPD) has launched an expanded gene-fusion panel (Fusion 2.0) which includes translocations that are diagnostically and clinically relevant in sarcomas. Fusion panel 1 included 17 targeted genes and partners for lung, brain, and prostate disease groups. Fusion panel 2.0 now includes 56 target genes and partners and adds thyroid and sarcoma as disease groups.